Company intelligence / Profile preview

Ophiomics

Ownership: Private
Development stage: Commercial

Overview

Ophiomics has developed proprietary platforms for the rapid development of AI-powered, omics-based diagnostic products focused on precision medicine in hepatology. Their solutions are clinically validated and support diagnosis, prognosis, treatment selection, and follow-up for liver diseases—especially liver cancer. They have proof-of-concept results and conduct clinical validation studies with their ISO 13485–certified pilot manufacturing facility.

Therapeutic areas: OncologyGastroenterology
Modalities: Diagnostic deviceBioinformatics-based diagnosticsGenomic test (nucleic acid-based biomarkers)Artificial intelligence-powered algorithms
Industry: Molecular Diagnostics

Drug pipeline

1 asset

HepatoPredict

Commercial

Indications: Liver cancer

Partnerships

Collaborative relationships with Dx distributors

Beyond the preview

Go deeper on Ophiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophiomics.

Explore the full profile